Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.

[1]  J. Peres.  Lung cancer screening: ready for prime time? , 2011, Journal of the National Cancer Institute.

[2]  J. Mortensen,et al.  Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  A. Dirksen,et al.  Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial , 2010, Thorax.

[4]  F. Mottaghy,et al.  Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer , 2010, The Journal of Nuclear Medicine.

[5]  Y. Ung,et al.  Positron Emission Tomography in Staging Early Lung Cancer , 2009, Annals of Internal Medicine.

[6]  L. Santambrogio,et al.  Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness. , 2008, International surgery.

[7]  Y. Ung,et al.  18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. , 2007, Journal of the National Cancer Institute.

[8]  M. Lock,et al.  Systematic review of baseline low-dose CT lung cancer screening. , 2007, Lung cancer.

[9]  I. Bradbury,et al.  Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. , 2007, Health technology assessment.

[10]  F. Fazio,et al.  Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[11]  H. Groen,et al.  Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Munden,et al.  Imaging of the patient with non-small cell lung cancer. , 2005, Radiology.

[13]  A. Bernard,et al.  Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule , 2005, The European Journal of Health Economics.

[14]  T. Bilfinger,et al.  The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. , 2005, Chest.

[15]  S. Kosuda,et al.  Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma? , 2005, Annals of nuclear medicine.

[16]  C. Rowe,et al.  Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  F. Guillemin,et al.  Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. , 2005, Clinical radiology.

[18]  J. Bogaert,et al.  Role of computed tomography in lung cancer staging , 2004, Current opinion in pulmonary medicine.

[19]  M. King,et al.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Mathews,et al.  Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[21]  Y. Tsushima,et al.  Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[22]  F. Fazio,et al.  Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[23]  S. Kosuda,et al.  Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma—Reassessment based on the revised Japanese national insurance reimbursement system , 2003, Annals of nuclear medicine.

[24]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[25]  G. Bepler,et al.  A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[26]  M. Boers,et al.  Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Paul Barnett,et al.  Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules , 2003, Annals of Internal Medicine.

[28]  Sean D Sullivan,et al.  Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.

[29]  S. Kosuda,et al.  Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan , 2002, Annals of nuclear medicine.

[30]  K. Miles,et al.  Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[32]  M. Liebow,et al.  Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. , 2002, Mayo Clinic proceedings.

[33]  K. Miles.  An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. , 2001, Australasian radiology.

[34]  A. Gandjour,et al.  Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results , 2000, European Journal of Nuclear Medicine.

[35]  A. Gandjour,et al.  Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany , 2000, European Journal of Nuclear Medicine.

[36]  S. Sone,et al.  Characteristics of small lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. , 2000, The British journal of radiology.

[37]  S. Kosuda,et al.  Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. , 2000, Chest.

[38]  S. Kosuda,et al.  [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)]. , 1998, Kaku igaku. The Japanese journal of nuclear medicine.

[39]  J. Shepherd,et al.  Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. , 1998, The Annals of thoracic surgery.

[40]  P. Valk,et al.  Analytical decision model for the cost-effective management of solitary pulmonary nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  P. Valk,et al.  Cost-effectiveness of PET imaging in clinical oncology. , 1996, Nuclear medicine and biology.

[43]  N. Müller,et al.  Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. , 1994, Radiology.

[44]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[45]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[46]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[47]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[48]  F MURRAY,et al.  Diagnosis and treatment of lung cancer. , 1955, Geriatrics.

[49]  F. Kee,et al.  The value of positron emission tomography in patients with non-small cell lung cancer. , 2010, European journal of radiology.

[50]  Y. Lacasse,et al.  Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. , 2005, Canadian respiratory journal.

[51]  J. Hay,et al.  Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES , 2003, Journal of managed care pharmacy : JMCP.

[52]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Peto,et al.  Tobacco—the growing epidemic , 1999, Nature Medicine.

[54]  Douglas L. Weed,et al.  Methodologic Guidelines for Review Papers , 1997 .